These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28924374)

  • 1. No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study.
    Kruszelnicka O; Kuźma M; Pena IZ; Perera IB; Chyrchel B; Wieczorek-Surdacka E; Surdacki A
    Int J Med Sci; 2017; 14(10):1015-1021. PubMed ID: 28924374
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control.
    Barchetta I; Guglielmi C; Bertoccini L; Calella D; Manfrini S; Secchi C; Pozzilli P; Cavallo MG;
    Acta Diabetol; 2015 Oct; 52(5):873-80. PubMed ID: 25716766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients.
    Bilic-Curcic I; Berkovic MC
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):297-302. PubMed ID: 28982341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of proton pump inhibitor use in gastrointestinal polyps.
    Hsu WH; Wu IC; Kuo CH; Su YC; Lu CY; Kuo FC; Jan CM; Wang WM; Wu DC; Yu FJ
    Kaohsiung J Med Sci; 2010 Feb; 26(2):76-83. PubMed ID: 20123595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.
    Misra PS; Alam A; Lipman ML; Nessim SJ
    BMC Nephrol; 2015 Aug; 16():136. PubMed ID: 26268579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes.
    Villegas K; Meier JL; Long M; Lopez J; Swislocki A
    Metab Syndr Relat Disord; 2019 May; 17(4):192-196. PubMed ID: 30730235
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus.
    Han N; Oh M; Park SM; Kim YJ; Lee EJ; Kim TK; Kim TN; Kwon MJ; Kim MK; Lee SH; Rhee BD; Park JH
    Can J Diabetes; 2015 Feb; 39(1):24-8. PubMed ID: 25305802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function.
    Austin GL; Weiskopf JR; Czwornog JL
    J Clin Gastroenterol; 2018 Sep; 52(8):691-695. PubMed ID: 29099466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incretin effect in critically ill patients: a case-control study.
    Nielsen ST; Janum S; Krogh-Madsen R; Solomon TP; Møller K
    Crit Care; 2015 Nov; 19():402. PubMed ID: 26567860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease.
    Heldgaard PE; Olivarius Nde F; Hindsberger C; Henriksen JE
    Diabet Med; 2004 Apr; 21(4):363-70. PubMed ID: 15049940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.
    Kruszelnicka O; Świerszcz J; Bednarek J; Chyrchel B; Surdacki A; Nessler J
    Int J Mol Sci; 2016 Apr; 17(4):454. PubMed ID: 27092494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitors: impact on glucose metabolism.
    Boj-Carceller D
    Endocrine; 2013 Feb; 43(1):22-32. PubMed ID: 22886351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of proton pump inhibitor treatment on pancreatic beta-cell area and beta-cell proliferation in humans.
    Breuer TG; Borker L; Quast DR; Tannapfel A; Schmidt WE; Uhl W; Meier JJ
    Eur J Endocrinol; 2016 Nov; 175(5):467-76. PubMed ID: 27562401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Appearance of undiagnosed diabetes mellitus in the population of professionally active people in the urban areas].
    Wierusz-Wysocka B; Zozulińska D; Knast B; Pisarczyk-Wiza D
    Pol Arch Med Wewn; 2001 Sep; 106(3):815-21. PubMed ID: 11928591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged utilization of proton pump inhibitors in patients with ischemic and valvular heart disease is associated with surgical treatments, weight loss and aggravates anemia.
    Boban M; Zulj M; Persic V; Medved I; Zekanovic D; Vcev A
    Int J Cardiol; 2016 Sep; 219():277-81. PubMed ID: 27343420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.
    Rhee NA; Østoft SH; Holst JJ; Deacon CF; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Sep; 171(3):353-62. PubMed ID: 24935932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.